Join
Live feed
·
INSIDERFilingvia Quantisnow
Mersana Therapeutics Inc. logo

SVP, Chief Development Officer Bala Mohan converted options into 250 shares and sold $762 worth of shares (77 units at $9.90), increasing direct ownership by 6% to 2,922 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRSN (Mersana Therapeutics Inc.) and more on Quantisnow.